Biovie Inc (BIVI)

Currency in USD
0.9644
-0.2056(-17.57%)
Closed·
1.3600+0.3956(+41.02%)
·
Unusual Pre-Market activity
Unusual trading volume
BIVI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.94501.1400
52 wk Range
0.82003.7900
Key Statistics
Prev. Close
0.9644
Open
1.13
Day's Range
0.945-1.14
52 wk Range
0.82-3.79
Volume
10.54M
Average Volume (3m)
2.62M
1-Year Change
-39.3459%
Book Value / Share
1.36
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIVI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.2550
Upside
+444.90%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Biovie Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 5.2550
(+444.90% Upside)

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
-0.71 / -0.52
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BIVI Income Statement

Compare BIVI to Peers and Sector

Metrics to compare
BIVI
Peers
Sector
Relationship
P/E Ratio
−0.3x−2.7x−0.3x
PEG Ratio
0.00−0.010.00
Price/Book
0.7x2.1x2.6x
Price / LTM Sales
-71.5x3.1x
Upside (Analyst Target)
-139.9%50.4%
Fair Value Upside
Unlock13.5%6.4%Unlock

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2b clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
177.45K2.35%207.62K
Other Institutional Investors
891.10K11.82%1.04M
Public Companies & Retail Investors
6.47M85.83%7.57M
Total
7.54M100.00%8.82M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Diametric Capital, LP4.91%370,000433
Vanguard Capital Management, LLC1.61%121,624142

People Also Watch

0.700
OTLK
+4.17%
0.504
ATYR
-2.89%
143.34
SPCX
-1.98%
1.35
BMEA
0.00%
23.360
PL
-4.18%

FAQ

What Is the Biovie (BIVI) Stock Price Today?

The Biovie stock price today is 0.9644 USD.

What Stock Exchange Does Biovie Trade On?

Biovie is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Biovie?

The stock symbol for Biovie is "BIVI."

What Is the Biovie Market Cap?

As of today, Biovie market cap is 7.2700M USD.

What Is Biovie's Earnings Per Share (TTM)?

The Biovie EPS (TTM) is -3.0500.

From a Technical Analysis Perspective, Is BIVI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Biovie Stock Split?

Biovie has split 3 times.

How Many Employees Does Biovie Have?

Biovie has 13 employees.

What is the current trading status of Biovie (BIVI)?

As of Aug 19, 2026, Biovie (BIVI) is trading at a price of 0.9644 USD, with a previous close of 0.9644 USD. The stock has fluctuated within a day range of 0.9450 USD to 1.1400 USD, while its 52-week range spans from 0.8200 USD to 3.7900 USD.

What Is Biovie (BIVI) Price Target According to Analysts?

The average 12-month price target for Biovie is 5.2550 USD, with a high estimate of 5.51 USD and a low estimate of 5 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +444.90% Upside potential.

What Is the BIVI Premarket Price?

BIVI's last pre-market stock price is 1.3600 USD. The pre-market share volume is 12,120,000.0000, and the stock has decreased by 0.3956, or 41.0200%.

What Is the BIVI After Hours Price?

BIVI's last after hours stock price is 1.6000 USD, the stock has decreased by 0.6356, or 65.9100%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.